BRAF and melanoma: The FDA-approved BRAF inhibitors dabrafenib, vemurafenib, encorafenib, and binimetinib are used in the treatment of patients with BRAF-mutant melanoma by selectively targeting BRAF kinase and interfering MAPK signalling pathway.